Weekly Aspergillosis Research Update (7–11 April 2026)

Last reviewed: April 2026
Audience: Patients, carers, GPs, specialist nurses, and healthcare professionals

Key Points (Summary)

Invasive pulmonary aspergillosis (IPA) can closely mimic other serious infections, including miliary tuberculosis, particularly in highly immunocompromised patients.
Metagenomic next-generation sequencing (mNGS) is emerging as a valuable diagnostic tool in complex or unclear cases, though it is not yet widely available.
Bruton tyrosine kinase (BTK) inhibitors are associated with a measurable risk of invasive fungal infections, with aspergillosis the most frequently reported.
Host genetics (e.g. toll-like receptor variants) may influence susceptibility to invasive fungal disease, but this is not yet used clinically.
Azole antifungal drugs remain high-risk for drug–drug interactions, particularly in patients receiving cancer therapies.
Basic science research continues to identify new fungal targets and pathways, which may inform future treatments.

Diagnosis and difficult cases
Treatment-related risk and immunosuppression
Genetics and susceptibility
Asthma and Aspergillus sensitisation
Drug interactions
Emerging research and future treatments
What this means for patients
When to seek medical advice

Diagnosis and difficult cases

When aspergillosis looks like something else

A case report
(Ji H et al., 2026 – full text)
describes a patient with acute leukaemia who developed widespread “miliary” lung nodules—an imaging pattern classically associated with tuberculosis.

Despite this, the final diagnosis was invasive pulmonary aspergillosis (IPA).

Clinical interpretation

Radiological appearances in immunocompromised patients can be non-specific.
Aspergillosis may present without classic features such as halo signs or cavitation.
Coinfection (e.g. TB + fungal disease) can further complicate interpretation.

This reinforces an important principle in clinical practice: lack of response to treatment should prompt reconsideration of the diagnosis.

The emerging role of mNGS

In this case, metagenomic next-generation sequencing (mNGS) helped establish the diagnosis by detecting fungal DNA directly from clinical samples.

Strengths of mNGS

Broad pathogen detection (fungi, bacteria, viruses)
Useful in culture-negative infections
Can identify unexpected pathogens

Current limitations

Limited availability outside specialist centres
Cost and turnaround time
Interpretation challenges (distinguishing infection from colonisation)

Bottom line: mNGS is promising, but currently complements rather than replaces standard diagnostics (culture, PCR, antigen testing).

Treatment-related risk and immunosuppression

BTK inhibitors and invasive fungal infection

A systematic review and meta-analysis
(PMID: 41954633)
including over 23,000 patients found that:

Aspergillosis was the most commonly reported invasive fungal infection
Central nervous system involvement was reported in a subset

Why BTK inhibitors increase risk

They impair B-cell signalling
They affect macrophage and neutrophil function
This reduces the body’s ability to control fungal spores

Clinical implications

Risk stratification is important
Some patients may require antifungal prophylaxis
Early recognition of symptoms is critical

This aligns with increasing recognition that modern targeted therapies can have unintended immunological effects.

Genetics and susceptibility

The role of innate immunity

A systematic review
(PMID: 41962654)
examined toll-like receptor (TLR) polymorphisms and fungal infection risk.

TLRs are part of the innate immune system and are responsible for recognising fungal components such as:

β-glucans
Cell wall proteins

Key insight

Certain genetic variants were more frequently reported in patients with invasive aspergillosis

Important context:

This does not yet translate into routine testing
It may become relevant in the future for personalised risk prediction

Asthma and Aspergillus sensitisation

A 12-week prospective study
(PMID: 41949214)
found that:

~29% of asthma patients were sensitised to Aspergillus fumigatus
No significant short-term differences in outcomes were seen compared to non-sensitised patients

Interpretation

Sensitisation alone does not necessarily indicate active disease
Clinical context remains critical

Important distinction:

Sensitisation = immune response to Aspergillus
ABPA (Allergic Bronchopulmonary Aspergillosis) = a specific inflammatory disease requiring treatment

Drug interactions

Itraconazole and erlotinib interaction

A case report
(PMID: 41953502)
demonstrated increased exposure to erlotinib when co-administered with itraconazole.

Mechanism

Itraconazole inhibits CYP3A4
This reduces drug metabolism
Drug levels rise, increasing risk of toxicity

Clinical message

Always review medications when starting antifungals
Particular caution is needed in cancer, transplant, and multi-morbid patients

Useful tool:
Antifungal Interactions Checker

Emerging research and future treatments

Epigenetic regulation in Aspergillus fumigatus

A study
(PMID: 41928566)
identified the role of HosA in regulating fungal growth and virulence.

This type of work helps identify:

Potential drug targets
Mechanisms of antifungal resistance

New experimental antifungal compounds

A review
(Full text (PMC))
discusses sodium new houttuyfonate (SNH), which has shown activity in animal models of invasive aspergillosis.

Important caution:

This is early-stage research
It is not available as a treatment

What this means for patients

Aspergillosis can sometimes be difficult to diagnose, especially if symptoms overlap with other conditions.
If treatment is not working, your medical team may need to review or repeat tests.
Some medications (especially for cancer or immune conditions) can increase risk of fungal infection.
Antifungal medications are effective but require careful monitoring for interactions.
New research is promising, but most advances take time to reach routine care.

When to seek medical advice

Seek medical attention urgently if you have:

Worsening breathlessness
Persistent fever
Coughing up blood
New chest pain
Symptoms not improving with treatment

If you are immunocompromised, symptoms may progress quickly and should be assessed promptly.

References

Author & Review

This article is part of the Aspergillosis.org weekly research update series. It is intended for general educational purposes and reflects a structured summary of recent research.

Disclaimer: This content is not a substitute for medical advice. Always consult your healthcare team for individual care decisions.

Path: Start » Weekly Updates » Weekly Aspergillosis Research Update (7–11 April 2026)